BioNTech stock price target raised to $120 from $110 at TD Cowen on Comirnaty sales

Published 04/08/2025, 21:46
BioNTech stock price target raised to $120 from $110 at TD Cowen on Comirnaty sales

Investing.com - TD Cowen raised its price target on BioNTech (NASDAQ:BNTX) to $120.00 from $110.00 on Monday, while maintaining a Hold rating on the stock. According to InvestingPro data, analyst targets for BioNTech range from $112 to $172, with the company maintaining a robust financial position, holding more cash than debt on its balance sheet.

The firm cited BioNTech’s second-quarter Comirnaty sales of €153 million, which exceeded consensus estimates of €85 million and TD Cowen’s own projection of €70 million.

BioNTech reaffirmed its fiscal year 2025 guidance, according to TD Cowen’s research note.

The company has several upcoming data readouts scheduled, including results for BNT327 from global Phase 2 dose optimization trials in SCLC/TNBC in the second half of 2025, BNT111 in R/R melanoma at ESMO, and BNT122 in 1L melanoma at ESMO and adjuvant CRC in late 2025 or early 2026.

TD Cowen indicated it has increased estimates for BNT327 and adjusted its model to account for BioNTech’s collaboration with Bristol Myers (NYSE:BMY) Squibb, contributing to the $10 increase in the price target.

In other recent news, BioNTech reported its second-quarter 2025 financial results, revealing a significant revenue increase. The company achieved revenues of €260.8 million, which more than doubled compared to the previous year and surpassed analyst estimates of €137.9 million. Despite this revenue growth, BioNTech posted a net loss of €386.6 million, translating to a loss of -€1.60 per share, slightly worse than the anticipated -€1.41 per share. In addition to the earnings report, BioNTech’s outlook was bolstered by a deal with Bristol Myers. Clear Street responded to these developments by raising its price target for BioNTech from $181 to $185 while maintaining a Buy rating. These recent events have contributed to a positive outlook for the company’s future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.